Barclays’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.69M | Buy |
21,700
+17,700
| +443% | +$8.25M | ﹤0.01% | 1466 |
|
|
2025
Q4 | $1.81M | Hold |
4,000
| – | – | ﹤0.01% | 3010 |
|
|
2025
Q3 | $1.57M | Hold |
4,000
| – | – | ﹤0.01% | 3059 |
|
|
2025
Q2 | $1.78M | Hold |
4,000
| – | – | ﹤0.01% | 2938 |
|
|
2025
Q1 | $1.94M | Sell |
4,000
-23,900
| -86% | -$11.1M | ﹤0.01% | 2658 |
|
|
2024
Q4 | $11.2M | Buy |
27,900
+6,000
| +27% | +$2.78M | ﹤0.01% | 1491 |
|
|
2024
Q3 | $10.2M | Buy |
+21,900
| New | +$10.5M | ﹤0.01% | 1474 |
|
|
2024
Q2 | – | Sell |
-49,800
| Closed | -$20.8M | – | 5331 |
|
|
2024
Q1 | $20.8M | Buy |
49,800
+13,800
| +38% | +$5.83M | 0.01% | 966 |
|
|
2023
Q4 | $14.6M | Buy |
36,000
+13,400
| +59% | +$4.95M | 0.01% | 1241 |
|
|
2023
Q3 | $7.86M | Buy |
+22,600
| New | +$7.9M | ﹤0.01% | 1101 |
|
|
2023
Q1 | – | Sell |
-33,000
| Closed | -$9.53M | – | 5376 |
|
|
2022
Q4 | $9.53M | Hold |
33,000
| – | – | ﹤0.01% | 1229 |
|
|
2022
Q3 | $9.55M | Sell |
33,000
-73,800
| -69% | -$21.2M | 0.01% | 875 |
|
|
2022
Q2 | $30.1M | Buy |
+106,800
| New | +$28.6M | 0.02% | 557 |
|
|
2022
Q1 | – | Sell |
-167,400
| Closed | -$36.8M | – | 5666 |
|
|
2021
Q4 | $36.8M | Buy |
+167,400
| New | +$32.6M | 0.01% | 687 |
|
|
2021
Q3 | – | Sell |
-25,000
| Closed | -$5.04M | – | 5043 |
|
|
2021
Q2 | $5.04M | Buy |
25,000
+24,400
| +4,067% | +$5.1M | ﹤0.01% | 1579 |
|
|
2021
Q1 | $128K | Sell |
600
-54,400
| -99% | -$11.9M | ﹤0.01% | 3900 |
|
|
2020
Q4 | $13M | Hold |
55,000
| – | – | 0.01% | 1044 |
|
|
2020
Q3 | $15M | Buy |
55,000
+600
| +1% | +$166K | 0.01% | 867 |
|
|
2020
Q2 | $15.8M | Sell |
54,400
-13,600
| -20% | -$3.69M | 0.01% | 742 |
|
|
2020
Q1 | $16.2M | Sell |
68,000
-3,400
| -5% | -$780K | 0.01% | 731 |
|
|
2019
Q4 | $15.6M | Buy |
71,400
+18,900
| +36% | +$3.83M | 0.01% | 1091 |
|
|
2019
Q3 | $8.89M | Buy |
52,500
+21,400
| +69% | +$3.79M | 0.01% | 1375 |
|
|
2019
Q2 | $5.7M | Sell |
31,100
-78,700
| -72% | -$13.8M | ﹤0.01% | 1750 |
|
|
2019
Q1 | $20.2M | Sell |
109,800
-7,900
| -7% | -$1.46M | 0.01% | 850 |
|
|
2018
Q4 | $19.5M | Sell |
117,700
-65,900
| -36% | -$11.4M | 0.02% | 761 |
|
|
2018
Q3 | $35.4M | Buy |
183,600
+124,600
| +211% | +$22.2M | 0.02% | 572 |
|
|
2018
Q2 | $10M | Buy |
59,000
+8,400
| +17% | +$1.3M | 0.01% | 1224 |
|
|
2018
Q1 | $8.25M | Sell |
50,600
-7,500
| -13% | -$1.23M | 0.01% | 1291 |
|
|
2017
Q4 | $8.71M | Sell |
58,100
-26,400
| -31% | -$3.91M | 0.01% | 1262 |
|
|
2017
Q3 | $12.8M | Sell |
84,500
-9,000
| -10% | -$1.35M | 0.01% | 901 |
|
|
2017
Q2 | $12.1M | Sell |
93,500
-136,300
| -59% | -$16.4M | 0.01% | 863 |
|
|
2017
Q1 | $25.1M | Buy |
229,800
+156,900
| +215% | +$13.8M | 0.03% | 470 |
|
|
2016
Q4 | $5.37M | Sell |
72,900
-7,900
| -10% | -$643K | 0.01% | 1340 |
|
|
2016
Q3 | $7.05M | Buy |
80,800
+48,600
| +151% | +$4.59M | 0.01% | 1068 |
|
|
2016
Q2 | $2.77M | Buy |
32,200
+400
| +1% | +$34.6K | ﹤0.01% | 1750 |
|
|
2016
Q1 | $2.51M | Sell |
31,800
-17,200
| -35% | -$1.56M | ﹤0.01% | 1724 |
|
|
2015
Q4 | $6.13M | Sell |
49,000
-2,700
| -5% | -$326K | 0.01% | 1176 |
|
|
2015
Q3 | $5.38M | Buy |
51,700
+12,400
| +32% | +$1.59M | 0.01% | 1320 |
|
|
2015
Q2 | $4.83M | Sell |
39,300
-66,100
| -63% | -$8.33M | 0.01% | 1507 |
|
|
2015
Q1 | $12.3M | Sell |
105,400
-304,100
| -74% | -$36.4M | 0.01% | 956 |
|
|
2014
Q4 | $48.3M | Sell |
409,500
-19,900
| -5% | -$2.24M | 0.05% | 362 |
|
|
2014
Q3 | $48.1M | Sell |
429,400
-640,300
| -60% | -$61M | 0.05% | 338 |
|
|
2014
Q2 | $101M | Buy |
1,069,700
+600,900
| +128% | +$42.1M | 0.11% | 145 |
|
|
2014
Q1 | $32.8M | Buy |
468,800
+96,600
| +26% | +$7.65M | 0.04% | 446 |
|
|
2013
Q4 | $27.5M | Buy |
372,200
+39,200
| +12% | +$2.73M | 0.03% | 589 |
|
|
2013
Q3 | $25M | Sell |
333,000
-180,200
| -35% | -$14.3M | 0.03% | 557 |
|
|
2013
Q2 | $41.1M | Buy |
+513,200
| New | +$37.8M | 0.05% | 317 |
|
Other funds holding VRTX
VCM
VPM
Barclays's VRTX Position: Q1 2026 in Review
Barclays reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q1 2026, selling an estimated $86M and leaving 663,263 shares worth $296M. The position accounts for 0.07% of the portfolio, ranked #204.
Barclays first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $437M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Barclays held 663,263 shares of Vertex Pharmaceuticals worth $296M as of Q1 2026.
- Barclays sold 184,495 Vertex Pharmaceuticals shares in Q1 2026, an estimated $86M.
- Vertex Pharmaceuticals made up 0.07% of Barclays's portfolio in Q1 2026, its #204 holding.
- Barclays first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Vertex Pharmaceuticals position peaked at $437M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.